NCT00620412已完成1 期
Lactobacillus GG to Enhance the Immunogenicity of Influenza Vaccine in Healthy Adults - Proof of Concept Study
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 52
- 主要终点
- To measure anti-influenza systemic and mucosal antibody responses 4 weeks after administration of influenza vaccine (LAIV) to healthy subjects aged 18-49 and to compare responses in subjects receiving Lactobacillus GG (LGG) versus placebo
研究概览
简要总结
The purpose of this study is to determine whether the food supplement called Lactobacillus rhamnosus GG (LGG) may help boost the effectiveness of the nasal flu vaccine. Preliminary data from several studies of healthy volunteers suggest that LGG boosts the immune response to vaccines. Fifty-two subjects will be recruited into the study, all will receive the nasal flu vaccine. Twenty-six will receive capsules that contain LGG, 26 will receive placebo capsules. Blood and nasal specimens will be collected weekly for four weeks and at eight weeks to evaluate the initial mucosal and systemic immune response to the immunization. This study will provide preliminary data on whether the immune response of healthy adults to the nasal influenza vaccine can be boosted by LGG.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 49 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Age 18-49 years
- •Available for clinic visits at Tufts-New England Medical Center
- •Written informed consent and Health Insurance Portability and Accountability Act (HIPAA) obtained
- •Ability of participant to understand and comply with the requirements of the protocol
排除标准
- •History of any medical conditions for which the CDC states should not be vaccinated with LAIV (asthma, reactive airways disease, other chronic disorders of the pulmonary or cardiovascular systems; metabolic diseases such as diabetes, renal dysfunction, and hemoglobinopathies; or persons with known or suspected immunodeficiency diseases)
- •Self-reported vaccination with the influenza vaccine for the current influenza season (2007-8); vaccination with any vaccine within the one month period prior to study enrollment or intent to receive any other vaccine during the study period; hypersensitivity to any influenza vaccine components including thimersol or egg or Guillain-Barre syndrome
- •Self-reported treatment with immunomodulator/immunosuppressor drugs (interleukins, corticosteriods (oral or inhaled)), G(M)-CSF in 4 weeks before enrollment or self-reported history of IL-2 administration within 5 years; use of theophylline preparations or warfarin because of the theoretical possibilities of enhanced drug effects and toxicities following influenza vaccination; medication use that might affect the immune response to a vaccine or effects of LGG (no antibiotics during the previous 4 weeks)
- •Current alcohol, substance abuse, or systemic/psychiatric illness that potentially could interfere with compliance and ability to make study visits
- •Health care or day care workers or close contacts with immunosuppressed persons because of the theoretical risk that LAIV could be transmitted to the immunosuppressed person and cause disease, per CDC recommendations
- •Use of LGG or other probiotics in 4 weeks before enrollment. Yogurt consumption is not an exclusion criteria, but subjects will be asked to avoid consumption of other lactobacilli and probiotic organisms during the study period
- •Abnormalities upon physical examination
- •Acute febrile illness on day of intended immunization - immunization deferred until illness resolved
- •Routine laboratory tests outside the limits outlined for this study:
- •hemoglobin >=11.5g/dL for women; >=13.5 g/dL for men
- •WBC 3,300-12,000 cells/mm^3
- •Differential within normal range
- •Platelets 125,000-550,000 /mm^3
- •ALT <= upper limit of normal
- •Serum creatinine <= upper limit of normal
- •Normal urinalysis (negative glucose, negative or trace protein, and negative or trace hemoglobin)
- •Negative beta-HCG pregnancy test (urine or serum) for women presumed to be of reproductive potential because LAIV is contraindicated in pregnant women
- •negative HIV test
- •negative hepatitis B surface antigen
- •negative anti-HCV
结局指标
主要结局
To measure anti-influenza systemic and mucosal antibody responses 4 weeks after administration of influenza vaccine (LAIV) to healthy subjects aged 18-49 and to compare responses in subjects receiving Lactobacillus GG (LGG) versus placebo
时间窗: 4 weeks
次要结局
- To assess time course of antibody response after administration of influenza vaccine (LAIV) and to compare responses in subjects receiving LGG versus placebo(2 weeks)
研究者
相似试验
已完成
4 期
The Use of Probiotics to Evaluate Colonization With Antimicrobial Resistant BacteriaInfectious Disease of Digestive TractNCT01551186Washington University School of Medicine103
已完成
不适用
Lactocare Baby Drops in Infants ColicInfant ColicNCT02839239Biocare Copenhagen A/S168
已完成
不适用
actobacillus supplement intake testJPRN-UMIN000025888Beauty & Health Research_Inc96
已完成
不适用
Effect of Lactobacillus on the Microbiome of Household Contacts Exposed to COVID-19MicrobiomeNCT04399252Duke University182
招募中
不适用
A Study to Evaluate the Impact of Lactobacillus Rhamnosus GG on Proton Pump Inhibitor-Induced Gut DysbiosisHealthyNCT05517928Mayo Clinic30